Journals / Psychiatry and behavioral sciences (Online) / 2020 / Cilt: 10 - Sayı: 2

Famotidine Improved Schizophrenia-Like Behaviors in Acute Ketamine Model of Schizophrenia in Rats

Pages
45–54
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our results indicated that beneficial effect of famotidine in previous clinical studies was confirmed in animal model of schizophrenia in rats, and suggested translational value of this study for potential antipsychotic effects of famotidine.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Schizophrenia is a devastating disorder with its positive (hallucination and delusion), negative (such as social withdrawal, anhedonia), and cognitive (learning and attention deficits) symptoms.
📊
Key Findings & Data:There is a limited number of studies showing the promising potential benefits of famotidine, an H2 receptor antagonist used for the treatment of peptic ulcer, in schizophrenic patients.
💡
Conclusion & Impact:Conclusion: Our results indicated that beneficial effect of famotidine in previous clinical studies was confirmed in animal model of schizophrenia in rats, and suggested translational value of this study for potential antipsychotic effects of famotidine.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Schizophrenia is a devastating disorder with its positive (hallucination and delusion), negative (such as social withdrawal, anhedonia), and cognitive (learning and attention deficits) symptoms. Although current antipsychotic drugs treat positive symptoms, negative and cognitive symptoms have remained untreated. There is a limited number of studies showing the promising potential benefits of famotidine, an H2 receptor antagonist used for the treatment of peptic ulcer, in schizophrenic patients. In our previous study, it was showed that famotidine might improve schizophrenia-induced molecular deficits on Akt/GSK-3β/β-Catenin signaling pathway in SH-SY5Y cells and there is no translational study examining this effects of famotidine. Hence this study was designed to investigate the effects of famotidine on schizophrenia-like behavioral deficits in the acute ketamine model of schizophrenia in rats. Methods: Male Sprague Dawley rats divided into the four groups as saline, famotidine, ketamine, ketamine+famotidine (n=8 per group). Prepulse inhibition (PPI) of acustic startle response, novel object recognition (NOR), fear conditioning (FC), and social interaction (SI) tests were performed to measure schizophrenia-like symptoms in rats. Ketamine (10 mg/kg) was administered 15 min before the PPI test or 15 mg/kg 30 min before the NOR, FC, and SI tests whereas famotidine (4.4 mg/kg) was administered 30 min before all behavioral tests. Results: Ketamine decreased the PPI (%) at +8 dB (p<0.01) and +16 dB (p<0.001) prepulse intensities compared to saline and famotidine treated group had higher (p<0.05) PPI (%) at +16dB prepulse intensity compared to ketamine. In NOR test, ketamine injected rats did not cause an increase in time spent with novel objects compared to familiar ones. In contrast, saline and famotidine pretreated rats spent more (p<0.05 and p<0.01) time with a novel object than a familiar one. In FC, ketamine decreased the freezing time (p<0.05) compared to saline, while famotidine pretreatment found to be ineffective. In SI, ketamine caused a decrease in sniffing and total interaction compared to control, while famotidine pretreatment increased (p<0.05) the sniffing behavior compared to the ketamine group. Conclusion: Our results indicated that beneficial effect of famotidine in previous clinical studies was confirmed in animal model of schizophrenia in rats, and suggested translational value of this study for potential antipsychotic effects of famotidine.

🔖

Cite This Article

ÜNAL, G., ARICIOĞLU, F. (2020). Famotidine Improved Schizophrenia-Like Behaviors in Acute Ketamine Model of Schizophrenia in Rats. Psychiatry and behavioral sciences (Online), Cilt: 10 - Sayı: 2, 45–54. https://ajindex.com/articles/302871

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. van Os J, Kapur S. Schizophrenia. Lancet. 2009;374(9690):635– 645. Stahl SM. Beyond the dopamine hypothesis of schizophrenia to three neural networks of psychosis: dopamine, serotonin, and glutamate. CNS Spectr. 2018;23(3):187–191.
  2. Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, Neill JC. NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology. 2018;142:41–62.
  3. Koychev I, William Deakin JF, El-Deredy W, Haenschel C. Effects of acute ketamine infusion on visual working memory: event-related potentials. Biol Psychiatry Cogn Neurosci Neuroimaging. 2017;2(3):253–262.
  4. Nikiforuk A, Kos T, Fijał K, Hołuj M, Rafa D, Popik P. Effects of the selective 5-HT7 receptor antagonist SB-269970 and amisulpride on ketamine-induced schizophrenia-like deficits in rats. PLoS One. 2013;8(6):e66695. Braff DL. Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr Top Behav Neurosci. 2010;4:349–371.
  5. Mansbach RS, Geyer MA. Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacol. 1989;2(4):299–308. Geyer MA. The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps? Neurotox Res. 2006;10(3):211–220.
  6. Keefe RS, Harvey PD. Cognitive impairment in schizophrenia. In: Geyer M., Gross G., editors. Novel antischizophrenia treatments, Handbook of Experimental Pharmacology. Berlin: Springer; 2012, p. 11–37.
  7. Redrobe JP, Bull S, Plath N. Translational aspects of the novel object recognition task in rats abstinent following sub-chronic treatment with phencyclidine (PCP): effects of modafinil and relevance to cognitive deficits in schizophrenia. Front Psychiatry. 2010;1:146. Cohen SJ, Stackman RW Jr. Assessing rodent hippocampal involvement in the novel object recognition task. A review. Behav Brain Res. 2015;285:105–117.
  8. Neill JC, Barnes S, Cook S, et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther. 2010;128:419– 432. Sanger DJ, Joly D. Effects of NMDA receptor antagonists and sigma ligands on the acquisition of conditioned fear in mice. Psychopharmacology (Berl). 1991;104(1):27–34. doi:10.1007/ bf02244550. Millan MJ, Fone K, Steckler T, et al. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol